Plasma urate and progression of mild cognitive impairment

Neurodegenerative Diseases

Volumn 6, Issue 1-2, 2008, Pages 23-28

  Irizarry, Michael C ^a,f   Raman, Rema ^c,d   Schwarzschild, Michael A ^a   Becerra, Lida M ^c   Thomas, Ronald G ^c,d   Peterson, Ronald C ^e   Ascherio, Alberto ^b   Aisen, Paul S ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Mayo Clinic   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Mild cognitive impairment; Oxidative stress; Urate

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; PLACEBO; URATE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; RISK REDUCTION; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BOSTON; COGNITION DISORDERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; PREVALENCE; SURVIVAL ANALYSIS; URIC ACID; VITAMIN E;

EID: 57449110949     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000170883     Document Type: Article

References (20)

1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO: Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556.
2. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia - mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
3. Irizarry MC, Hyman BT: Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001;60:923-928.
4. Butterfield DA: Oxidative stress in neurodegenerative disorders. Antioxid Redox Signal 2006;8:1971-1973.
5. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972-976.
6. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU: Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-348.
7. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, Griffiths H, Senin U, Sies H, Mecocci P: Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004;18:265-270.
8. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003;24:915-919.
9. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
10. Davis JW, Grandinetti A, Waslien CJ, Ross GW, White LR, Morens DM: Observations on Serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480-484.
11. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM: Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005;58:797-800.
12. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Parkinson's Study Group PRECEPT Investigators: Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. Arch Neurol 2008;65:716-723.
13. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
14. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
15. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
16. Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, Jinnah HA: Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007;69:1418-1423.
17. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU: Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-348.
18. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003;24:915-919.
19. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E: No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995;10:566-573.
20. Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, Pearlson GD: Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 2007;21:136-140.